首页> 美国政府科技报告 >Molecular Imaging of Ovarian Carcinoma Angiogenesis; Annual rept. 1 Feb 2006-31 Jan 2007
【24h】

Molecular Imaging of Ovarian Carcinoma Angiogenesis; Annual rept. 1 Feb 2006-31 Jan 2007

机译:卵巢癌血管生成的分子成像;年度报告。 2006年2月1日至2007年1月31日

获取原文

摘要

This purpose of this proposal is to use high resolution microPET technology to image ovarian cancer integrin expression in vivo. Ovarian cancer is angiogenesis dependent. Integrin , a key player in tumor angiogenesis and metastasis, has been identified as a target for diagnostic and therapeutic interventions for several highly proliferative and metastatic tumor types. The interaction between vitronectin and integrin is essential for ovarian cancer cell survival and invasion. The integrin expression has been identified as a marker of poor prognosis in advanced-stage ovarian cancer. Its role in ovarian cancer development and as treatment target is under-developed. Specific Aim 1: To develop and optimize 18F-labeled RGD peptides for ovarian carcinoma targeting. Specific Aim 2: To test 18F-RGD peptide tracers in ovarian carcinoma models of different tumor integrin &(number sign)945;v&(number sign)946;3 expression levels in order to correlate the magnitude of tumor uptake with receptor density. Major Findings: In year 1, we have synthesized a series of multimeric RGD peptides with high integrin alphavbeta3 affinity/specificity and labeled these peptides with F-18 for PET imaging of integrin expression in vivo (Aim 1). We have also established several ovarian cancer models with differentiated integrin levels (Aim 2). Further test of the optimal radiotracer in different ovarian cancer models to correlate the tracer uptake with tumor integrin expression is currently underway (Aim 2).

著录项

相似文献

  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号